{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:10:46Z","timestamp":1794492646688,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004398","name":"The Mitsubishi Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004398","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The accurate and prompt diagnosis of SARS-CoV-2 infection is required for the control and treatment of the coronavirus infection disease 2019 (COVID-19). In this study, we aimed to investigate the time courses of the anti-severe acute corona respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG titers and to evaluate the sensitivity and specificity of such tests according to the specific day after the onset of COVID-19 among a patient population in Japan. We measured the titers of SARS-CoV-2 IgM and IgG in sera from 105 subjects, including 26 symptomatic COVID-19 patients, using chemiluminescent immunoassay (CLIA) methods utilizing magnetic beads coated with SARS-CoV-2 nucleocapsid protein and spike protein. The results of a ROC analysis suggested the possibility that the cutoff values in Japan might be lower than the manufacturer\u2019s reported cutoff (10\u00a0AU\/mL): 1 \u00a0AU\/mL for IgM and 5 \u00a0AU\/mL for IgG. The sensitivity of the test before Day 8 after symptom onset was less than 50%; at Days 9\u201310, however, we obtained a much higher sensitivity of 81.8% for both IgM and IgG. At 15\u00a0days or later after symptom onset, the SARS-CoV-2 IgG test had a sensitivity of 100%. These results suggest that if the number of days since disease onset is taken into consideration, these antibody tests could be very useful for the diagnosis of COVID-19 and similar diseases.<\/jats:p>","DOI":"10.1038\/s41598-021-82428-5","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T13:21:09Z","timestamp":1612272069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan"],"prefix":"10.1038","volume":"11","author":[{"given":"Yuki","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kurano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Nagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"82428_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13091","author":"G Pascarella","year":"2020","unstructured":"Pascarella, G. et al. COVID-19 diagnosis and management: a comprehensive review. J. Intern. Med. https:\/\/doi.org\/10.1111\/joim.13091 (2020).","journal-title":"J. Intern. Med."},{"key":"82428_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.3786","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA https:\/\/doi.org\/10.1001\/jama.2020.3786 (2020).","journal-title":"JAMA"},{"key":"82428_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.05.001","author":"E Pasomsub","year":"2020","unstructured":"Pasomsub, E. et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2020.05.001 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"82428_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"82428_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa489","author":"J Qu","year":"2020","unstructured":"Qu, J. et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa489 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"82428_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s1473-3099(20)30196-1","volume":"20","author":"KK-W To","year":"2020","unstructured":"To, K.K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565\u2013574. https:\/\/doi.org\/10.1016\/s1473-3099(20)30196-1 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"82428_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00461-20","author":"W Liu","year":"2020","unstructured":"Liu, W. et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/jcm.00461-20 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"82428_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10050319","author":"PI Kontou","year":"2020","unstructured":"Kontou, P. I., Braliou, G. G., Dimou, N. L., Nikolopoulos, G. & Bagos, P. G. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics (Basel) https:\/\/doi.org\/10.3390\/diagnostics10050319 (2020).","journal-title":"Diagnostics (Basel)"},{"key":"82428_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2020.03.065","volume":"94","author":"Y Jin","year":"2020","unstructured":"Jin, Y. et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int. J. Infect. Dis. 94, 49\u201352. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.065 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"82428_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1469-0691.2004.01009.x","volume":"10","author":"PR Hsueh","year":"2004","unstructured":"Hsueh, P. R., Huang, L. M., Chen, P. J., Kao, C. L. & Yang, P. C. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin. Microbiol. Infect. 10, 1062\u20131066. https:\/\/doi.org\/10.1111\/j.1469-0691.2004.01009.x (2004).","journal-title":"Clin. Microbiol. Infect."},{"key":"82428_CR11","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3201\/eid2112.151421","volume":"21","author":"WB Park","year":"2015","unstructured":"Park, W. B. et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg. Infect. Dis. 21, 2186\u20132189. https:\/\/doi.org\/10.3201\/eid2112.151421 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"82428_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jiph.2016.04.005","volume":"9","author":"S Al Johani","year":"2016","unstructured":"Al Johani, S. & Hajeer, A. H. MERS-CoV diagnosis: an update. J. Infect. Public Health 9, 216\u2013219. https:\/\/doi.org\/10.1016\/j.jiph.2016.04.005 (2016).","journal-title":"J. Infect. Public Health"},{"key":"82428_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848. https:\/\/doi.org\/10.1038\/s41591-020-0897-1 (2020).","journal-title":"Nat. Med."},{"key":"82428_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1101\/2020.03.12.20035048","volume":"7","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front. Mol. Biosci.\u00a07, 157.\u00a0https:\/\/doi.org\/10.1101\/2020.03.12.20035048 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"82428_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/infdis\/jiaa229","volume":"222","author":"G Zhang","year":"2020","unstructured":"Zhang, G., Nie, S., Zhang, Z. & Zhang, Z. Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J. Infect. Dis. 222, 183\u2013188. https:\/\/doi.org\/10.1093\/infdis\/jiaa229 (2020).","journal-title":"J. Infect. Dis."},{"key":"82428_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.04.20030916","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Serological detection of 2019-nCoV respond to the epidemic: a useful complement to nucleic acid testing. Int. Immunopharmacol. 88,\u00a0106861.\u00a0https:\/\/doi.org\/10.1101\/2020.03.04.20030916 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"82428_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature https:\/\/doi.org\/10.1038\/s41586-020-2349-y (2020).","journal-title":"Nature"},{"key":"82428_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25932","author":"M Infantino","year":"2020","unstructured":"Infantino, M. et al. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.25932 (2020).","journal-title":"J. Med. Virol."},{"key":"82428_CR19","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","volume":"56","author":"F Rees","year":"2017","unstructured":"Rees, F., Doherty, M., Grainge, M. J., Lanyon, P. & Zhang, W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 56, 1945\u20131961. https:\/\/doi.org\/10.1093\/rheumatology\/kex260 (2017).","journal-title":"Rheumatology (Oxford)"},{"key":"82428_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","volume":"15","author":"N Danchenko","year":"2006","unstructured":"Danchenko, N., Satia, J. A. & Anthony, M. S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15, 308\u2013318. https:\/\/doi.org\/10.1191\/0961203306lu2305xx (2006).","journal-title":"Lupus"},{"key":"82428_CR21","doi-asserted-by":"crossref","unstructured":"Zhou, F. Tracing Asymptomatic SARS-CoV-2 carriers among 3674 hospital staff. https:\/\/ssrn.com\/abstract=3582765 (2020).","DOI":"10.2139\/ssrn.3582765"},{"key":"82428_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1101\/2020.06.29.174888","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell\u00a0183,\u00a0158\u2013168.\u00a0https:\/\/doi.org\/10.1101\/2020.06.29.174888 (2020).","journal-title":"Cell"},{"key":"82428_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s13054-020-03078-z","volume":"24","author":"K Doi","year":"2020","unstructured":"Doi, K. et al. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit. Care 24, 392. https:\/\/doi.org\/10.1186\/s13054-020-03078-z (2020).","journal-title":"Crit. Care"},{"key":"82428_CR24","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1101\/2020.04.16.20067231","volume":"58","author":"C Qian","year":"2020","unstructured":"Qian, C. et al. Development and multicenter performance evaluation of the first fully automated SARS-CoV-2 IgM and IgG immunoassays. Clin. Chem. Lab. Med. 58, 1601\u20131607.\u00a0https:\/\/doi.org\/10.1515\/cclm-2020-0548\u00a0 (2020).","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82428-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:55:49Z","timestamp":1670036149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82428-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82428"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82428-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study is a collaborative research project among The University of Tokyo, Shenzhen YHLO Biotech Co., Ltd, and Medical & Biological Laboratories Co., Ltd. F. X. and F. H. are employees of Shenzhen YHLO Biotech Co., Ltd and Y. K. and J. O. are employees of Medical & Biological Laboratories Co., Ltd. Y.N., M. K., Y. M., T.S., R.Y., C.Q., N.Y., Y.N., H.O., K.M., Y.S., T.K., and Y.Y. declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2776"}}